A provocative analysis suggests the widespread adoption of GLP-1 drugs like Ozempic and Wegovy could trim airline fuel bills by reducing passenger weight, potentially passing savings to travelers. But industry experts debate whether the math adds up.
The industrial sector has been a quiet powerhouse, outpacing the broader market. Yet, amid the rally, some prominent names carry significant risks that warrant a closer look from investors.
As a Utah murder trial resumes, defense attorneys are pressing to remove the entire county prosecutor's office from the case, arguing the presence of a lead attorney's child at the crime scene creates an untenable conflict. Legal experts weigh the high bar for such motions.
As markets navigate a new year, analysts are eyeing potential outperformers. Amazon, BeOne Medicines, and Enterprise Products Partners emerge as compelling picks, each backed by distinct catalysts from AI to biotech breakthroughs.
House Speaker Mike Johnson expressed confidence that Republicans have the votes to pass a stopgap funding bill by Tuesday, aiming to end a partial government shutdown triggered over the weekend amid ongoing immigration policy disputes.
Glaukos shares have rebounded nearly 8% in a month, yet remain down sharply over the past year. A deep dive into the numbers reveals a stark contrast: a discounted cash flow model suggests significant upside, while price-to-sales metrics paint a picture of a richly valued stock. Investors are left weighing the promise of future glaucoma innovation against current market multiples.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.
A recent physician survey on renal denervation procedure volumes has prompted analysts to adopt a more measured view of Medtronic's near-term growth potential, even as the medical device giant remains a favored long-term holding.
New unemployment filings in Wisconsin edged higher last week, diverging from a slight national decline and highlighting ongoing labor market fluctuations across states.
CareDx CEO John Hanna sold over 19,000 shares under a pre-arranged trading plan, a move that comes as the transplant diagnostics firm posts strong revenue growth but continues to navigate a challenging stock market environment.
Producer prices rose 0.5% last month, exceeding forecasts and marking the quickest pace in three months, as a sharp jump in services costs offset stable goods prices, signaling persistent inflationary pressures in the pipeline.
While rising prices are felt at the checkout line, their long-term erosion of retirement savings is often overlooked. Experts warn that cumulative inflation across essential categories could create a six-figure shortfall for unprepared retirees.
The long-term strategic partnership will leverage IQVIA's data-as-a-service platform to unify and streamline commercial data across 59 countries, aiming to accelerate product launches and enhance decision-making for the pharmaceutical giant.
Signify N.V. shares fell sharply after the lighting giant's annual report revealed a significant earnings miss and a gloomy outlook, prompting analysts to cut revenue, EPS, and price targets.
A 23-year-old driver has been arrested on suspicion of driving under the influence after his vehicle crashed into a two-story Fairfield home, trapping a child under fallen debris. First responders successfully rescued the child, who was unharmed.
Lemonade's stock soared in January, propelled by the launch of a novel, usage-based insurance plan for Tesla vehicles that slashes premiums when Full Self-Driving is engaged, signaling a strategic pivot towards data-driven, autonomous future.
New industry figures show a surprising 30% surge in fixed-lens camera shipments, fueling overall market growth while DSLR sales continue their steep decline.
While voice-AI firms like SoundHound capture headlines, data analytics giant Palantir Technologies leverages deep government ties and enterprise contracts to build a potentially more resilient growth narrative in the volatile AI sector.
